$EXEL вышли хорошие новости о партнёрстве, на этом акция подрастёт сегодня • Exelixis (NASDAQ:EXEL) inks an agreement with Roche (OTCQX:RHHBY) aimed at evaluating the combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic solid tumors. • The companies will co-fund three late-stage studies in advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma.